Actively Recruiting

Phase Not Applicable
Age: 18Years - 89Years
All Genders
NCT07559630

Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS

Led by Jessica K. Stewart, MD · Updated on 2026-05-08

40

Participants Needed

1

Research Sites

283 weeks

Total Duration

On this page

Sponsors

J

Jessica K. Stewart, MD

Lead Sponsor

T

Terumo Medical Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this clinical trial is to compare two standard of care non-surgical treatments for hemorrhoidal bleeding: hemorrhoidal artery embolization (HAE) versus rubber band ligation (RBL). Directly comparing these two methods may help to clarify which treatment is better for controlling hemorrhoidal bleeding, reducing symptoms, and improving patients' quality of life. HAE is a standard minimally invasive procedure to put tiny particles or coils into the blood vessel that feeds a hemorrhoid to block the blood flow (embolization). This involves using a catheter inserted into an artery, using twilight (conscious) sedation. RBL is a standard procedure that involves using small rubber bands around the base of the hemorrhoids to cut off blood flow, causing it to shrink or shrivel.

CONDITIONS

Official Title

Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS

Who Can Participate

Age: 18Years - 89Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older and less than 90 years
  • Ability to provide written informed consent
  • Clinical history of chronic bleeding from internal hemorrhoids
  • Presence of Goligher grade II-III internal hemorrhoids
  • Failed conservative treatment such as fiber supplements, topical ointments, dietary changes, stool softeners, or warm baths
  • Ability to comply with all treatments and follow-up visits as determined by the principal investigator
Not Eligible

You will not qualify if you...

  • Moderate kidney function loss with estimated glomerular filtration rate below 45 mL/min
  • Significant arterial atherosclerosis limiting angiography
  • Known other causes of gastrointestinal bleeding
  • Allergy to iodinated contrast agents
  • Active infection or cancer
  • Pregnancy
  • Nicotine use within the last 12 months
  • Portal hypertension or rectal varices
  • Uncorrectable bleeding disorders (INR > 2; platelet count < 100,000; PTT > 40 seconds)
  • Abnormal findings on baseline CT angiography affecting treatment such as stenosis, occlusion, or hypoplasia of rectal arteries as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States, 90095

Actively Recruiting

Loading map...

Research Team

A

Aniket Joglekar, MD

CONTACT

S

Saima Chaabane, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here